- Home
- SDA vs AUPH Comparison
SDA vs AUPH Comparison
Compare SDA & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDA
- AUPH
- Stock Information
- Founded
- SDA 2007
- AUPH 1993
- Country
- SDA China
- AUPH Canada
- Employees
- SDA N/A
- AUPH N/A
- Industry
- SDA Blank Checks
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- SDA Finance
- AUPH Health Care
- Exchange
- SDA Nasdaq
- AUPH Nasdaq
- Market Cap
- SDA 293.6M
- AUPH 1.1B
- IPO Year
- SDA N/A
- AUPH 1999
- Fundamental
- Price
- SDA $2.62
- AUPH $7.58
- Analyst Decision
- SDA Buy
- AUPH Strong Buy
- Analyst Count
- SDA 1
- AUPH 2
- Target Price
- SDA $3.50
- AUPH $11.50
- AVG Volume (30 Days)
- SDA 81.8K
- AUPH 1.6M
- Earning Date
- SDA 05-19-2025
- AUPH 07-31-2025
- Dividend Yield
- SDA N/A
- AUPH N/A
- EPS Growth
- SDA N/A
- AUPH N/A
- EPS
- SDA N/A
- AUPH 0.27
- Revenue
- SDA $458,905,000.00
- AUPH $247,295,000.00
- Revenue This Year
- SDA $20.77
- AUPH $12.15
- Revenue Next Year
- SDA $19.32
- AUPH $18.31
- P/E Ratio
- SDA N/A
- AUPH $28.53
- Revenue Growth
- SDA 24.15
- AUPH 29.20
- 52 Week Low
- SDA $2.41
- AUPH $5.20
- 52 Week High
- SDA $11.74
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- SDA 34.72
- AUPH 40.36
- Support Level
- SDA $2.42
- AUPH $7.29
- Resistance Level
- SDA $2.66
- AUPH $8.86
- Average True Range (ATR)
- SDA 0.15
- AUPH 0.34
- MACD
- SDA -0.01
- AUPH -0.06
- Stochastic Oscillator
- SDA 8.62
- AUPH 19.37
About SDA SunCar Technology Group Inc.
SunCar Technology Group Inc operates digital automotive aftersales market service platform and vehicle insurance technology platform. It develops and operates online platforms that connect drivers in China with a range of aftermarket automotive services and insurance coverage options from a nationwide network of service providers. These comprehensive digital systems are built on SunCar's multi-tenant, cloud-based platform.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.